Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Unicycive Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Unicycive Therapeutics, Inc.’s stock price such as:

• Unicycive Therapeutics, Inc.’s current stock price and volume
• Why Unicycive Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for UNCY from analysts
• UNCY’s stock price momentum as measured by its relative strength

About Unicycive Therapeutics, Inc. (UNCY)

Before we jump into Unicycive Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.

Want to learn more about Unicycive Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Unicycive Therapeutics, Inc..

Unicycive Therapeutics, Inc.’s Stock Price as of Market Close

As of September 04, 2026, 4:00 PM, CST, Unicycive Therapeutics, Inc.’s stock price was $5.160.

Unicycive Therapeutics, Inc. is down 2.64% from its previous closing price of $5.300.

During the last market session, Unicycive Therapeutics, Inc.’s stock traded between $5.120 and $5.240. Currently, there are approximately 26.92 million shares outstanding for Unicycive Therapeutics, Inc..

Unicycive Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Unicycive Therapeutics, Inc. Stock Price History

Unicycive Therapeutics, Inc.’s (UNCY) price is currently down 0.77% so far this month.

During the month of September, Unicycive Therapeutics, Inc.’s stock price has reached a high of $5.340 and a low of $5.040.

Over the last year, Unicycive Therapeutics, Inc. has hit prices as high as $8.740 and as low as $3.710. Year to date, Unicycive Therapeutics, Inc.’s stock is down 10.57%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Unicycive Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 04, 2026, there was 1 analyst who downgraded Unicycive Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Unicycive Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Unicycive Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Unicycive Therapeutics, Inc. (UNCY) by visiting AAII Stock Evaluator.

Relative Price Strength of Unicycive Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 04, 2026, Unicycive Therapeutics, Inc. has a weighted four-quarter relative price strength of -2.83%, which translates to a Momentum Score of 42 and is considered to be Average.

Want to learn more about how Unicycive Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Unicycive Therapeutics, Inc. Stock Price: Bottom Line

As of September 4, 2026, Unicycive Therapeutics, Inc.’s stock price is $5.160, which is down 2.64% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Unicycive Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.